Amsterdam’s Healthplus.ai raises €2.3M to help hospitals predict post-surgery infection risk

Amsterdam’s Healthplus.ai has raised €2.3M to develop further and expand its AI technology, designed to support hospitals in managing surgical care.

Amsterdam’s digital healthtech and AI startup Healthplus.ai has secured €2.3M in funding to advance its AI-driven system for predicting post-surgery infection risk.

The round was led by Elevating Capital, with participation from LUMO Labs, ROM InWest, Pathena, and Leistone (Renza Family).

The Dutch startup’s ISO- and CE-certified AI system, PERISCOPE, works to lower complication rates, limit their consequences, shorten recovery periods, and bring down hospital costs.

Marcel Broersma, Founding Partner of Elevating Capital, says, “The investment in Healthplus.ai fits seamlessly within our strategy to invest in technology-driven companies with a demonstrable social impact. Healthplus.ai combines medical expertise with AI to make clinical risks predictable and to improve the quality and efficiency of healthcare processes.”

Reducing post-surgery infections

Founded in 2017 by Bart Geerts and Bart Steverink, Healthplus.ai is a medical technology company that works to reduce surgical complications and support full recovery after procedures. 

The company develops PERISCOPE, a CE-certified AI system that draws on electronic health record (EHR) data to estimate infection risk for each patient. This insight helps clinical teams act earlier, limit preventable harm, and guide safe discharge decisions.

Worldwide, one in three surgical patients experiences a complication, affecting more than 70 million people each year. Currently, five billion people still lack access to safe and affordable surgical and anaesthesia care. Infections remain the most common source of complications and are often identified many days after surgery.

PERISCOPE connects with hospital systems, fits into routine clinical processes, and adjusts to the patient population in each site to maintain consistent performance and regulatory alignment. Through this work, Healthplus.ai supports lower complication-related costs and strengthens the capacity of surgical teams.

The company operates in the Netherlands, Belgium, Denmark, and the UK. It is preparing further expansion across Nordic countries and North America, with early pilots underway in the United States.

Capital utilisation

Healthplus.ai plans to use the funds to expand its presence in Europe and the US by securing FDA clearance, improving system connections and linking its platform with major EHR providers such as Epic, Cerner, and ChipSoft.

The company is also widening its AI risk models to cover all parts of the perioperative process and various complication types.

Dr Bart Geerts, CEO and founder of Healthplus.ai, says, “With this late-seed investment, we’re strengthening our ability to bring clinically validated, regulatory-approved AI into everyday hospital practice. Our focus remains on close collaboration with surgeons, clinicians, and hospital IT teams to ensure that predictive insights truly improve patient outcomes.”

Roel Waals, Founding Partner of Elevating Capital, a new investor leading this key round, adds, “We see in this team strong execution capabilities, a scalable business model, and a clear contribution to the future of healthcare.”

What do the investors have to say?

Andy Lurling, founding partner of LUMO Labs, investor in Healthplus.ai since early 2022, says, “AI is critical to reform our healthcare system and to relief the increasing strain on nurses, doctors, and budgets, while upholding or even improving the high level of care we are used to. The adoption of MedTech AI requires not just two of the things Healthplus.ai does extremely well, that is, understanding the needs of the user and proving impact. It also requires two things that not all investors are too keen on: regulation and certification, processes that can be lengthy, unpredictable, and costly. This is why raising capital, even for the most successful MedTech AI startup, can be exceptionally challenging, especially in more risk adverse parts of the world, like here.”

“We are very excited to have these incredibly committed and experienced investors join the ranks. It is a true testament to Healthplus.ai’s stamina and achievements so far, and to their immense potential going forward.”

Antonio Murta, Co-Managing Partner and CEO of PATHENA, adds, “The ability to accurately predict infections in hospitalised patients is critical both to better protect their lives and to manage the cost of—and risk of resistance to—antibiotic use in a hospital setting. We are very happy to join the supporting squad of Healthplus.ai.”

Tim Heijink, General Manager at Leistone, mentions, “Healthplus.ai demonstrates that true healthcare innovation is not only about increasing efficiency but also about improving patient outcomes. This aligns perfectly with Leistone B.V.’s investment strategy: supporting technology-driven ventures that create real impact. We believe Healthplus.ai is a driver of a smarter, safer, and future-proof healthcare system.”

Sara Schaafsma, Investment Manager at ROM InWest, says, “We are excited about our investment in the North Holland–based Healthplus.ai. With unprecedented accuracy, Healthplus.ai predicts postoperative infections, enabling faster patient recovery, more efficient workflows for specialists, and easing the burden on the healthcare system. We are proud that through this investment, we can contribute to a future-proof healthcare system.”